S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
How major US stock indexes fared Thursday, 3/28/2024
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
How major US stock indexes fared Thursday, 3/28/2024
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
How major US stock indexes fared Thursday, 3/28/2024
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
How major US stock indexes fared Thursday, 3/28/2024
NASDAQ:DRRX

DURECT (DRRX) Stock Price, News & Analysis

$1.21
-0.13 (-9.70%)
(As of 03/28/2024 ET)
Today's Range
$1.17
$1.30
50-Day Range
$0.71
$1.37
52-Week Range
$0.47
$7.46
Volume
234,260 shs
Average Volume
185,749 shs
Market Capitalization
$36.09 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$35.00

DURECT MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
2,792.6% Upside
$35.00 Price Target
Short Interest
Healthy
3.72% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.19
Upright™ Environmental Score
News Sentiment
0.27mentions of DURECT in the last 14 days
Based on 11 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.46) to ($1.24) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.80 out of 5 stars

Medical Sector

262nd out of 938 stocks

Pharmaceutical Preparations Industry

121st out of 438 stocks

DRRX stock logo

About DURECT Stock (NASDAQ:DRRX)

DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine over three days in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Innocoll Pharmaceuticals Limited. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.

DRRX Stock Price History

DRRX Stock News Headlines

DURECT (NASDAQ:DRRX) Raised to "Hold" at StockNews.com
Durect: Q4 Earnings Insights
4x Better than Bitcoin
4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.
DURECT Corp. Q4 Loss decreases, beats estimates
DURECT Q4 2023 Earnings Preview
DURECT (DRRX) to Release Earnings on Wednesday
4x Better than Bitcoin
4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.
DURECT Co. (NASDAQ:DRRX) Short Interest Up 6.6% in February
DURECT (NASDAQ:DRRX) Downgraded by StockNews.com to "Sell"
DRRX Apr 2024 5.000 call
DRRX Apr 2024 0.500 put
DRRX Mar 2024 1.500 put
DURECT: Reading Into AHFIRM Mortality Rates
Recap: Durect Q3 Earnings
Durect Corp DRRX
See More Headlines
Receive DRRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for DURECT and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/01/2021
Today
3/29/2024
Next Earnings (Estimated)
5/13/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:DRRX
Employees
72
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$35.00
High Stock Price Target
$41.00
Low Stock Price Target
$27.00
Potential Upside/Downside
+2,792.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

Net Income
$-35,330,000.00
Net Margins
-398.65%
Pretax Margin
-398.65%

Debt

Sales & Book Value

Annual Sales
$19.28 million
Book Value
$1.10 per share

Miscellaneous

Free Float
28,546,000
Market Cap
$36.09 million
Optionable
Optionable
Beta
0.82
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

  • Dr. James E. Brown D.V.M. (Age 67)
    Co-Founder, CEO, President & Director
    Comp: $885.86k
  • Ms. Judy R. Joice (Age 67)
    Senior Vice President of Operations & Corporate Quality Assurance
    Comp: $451.82k
  • Dr. Norman L. Sussman M.D. (Age 71)
    Chief Medical Officer
    Comp: $587.95k
  • Mr. Timothy M. Papp M.B.A. (Age 48)
    CFO & Secretary
  • Ms. Jian Li M.B.A. (Age 54)
    Interim Principal Accounting Officer, Senior VP of Finance, Corporate Controller & Secretary
    Comp: $297.08k
  • Dr. WeiQi Lin M.D.
    Ph.D., Executive VP of Research & Development and Principal Scientist
  • Mr. Keith L. Lui M.B.A.
    Senior Vice President of Business Development, Commercial & Medical Affairs
  • Dr. Su Il Yum Ph.D. (Age 85)
    Executive Officer
    Comp: $331.74k

DRRX Stock Analysis - Frequently Asked Questions

Should I buy or sell DURECT stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DURECT in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" DRRX shares.
View DRRX analyst ratings
or view top-rated stocks.

What is DURECT's stock price target for 2024?

4 Wall Street research analysts have issued twelve-month target prices for DURECT's stock. Their DRRX share price targets range from $27.00 to $41.00. On average, they anticipate the company's share price to reach $35.00 in the next twelve months. This suggests a possible upside of 2,792.6% from the stock's current price.
View analysts price targets for DRRX
or view top-rated stocks among Wall Street analysts.

How have DRRX shares performed in 2024?

DURECT's stock was trading at $0.59 at the start of the year. Since then, DRRX shares have increased by 105.1% and is now trading at $1.21.
View the best growth stocks for 2024 here
.

When is DURECT's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024.
View our DRRX earnings forecast
.

How were DURECT's earnings last quarter?

DURECT Co. (NASDAQ:DRRX) issued its quarterly earnings data on Monday, November, 1st. The specialty pharmaceutical company reported ($0.40) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.50) by $0.10. The specialty pharmaceutical company earned $2.17 million during the quarter, compared to analyst estimates of $2.18 million. DURECT had a negative net margin of 398.65% and a negative trailing twelve-month return on equity of 289.99%. During the same period in the prior year, the firm posted ($0.50) earnings per share.

When did DURECT's stock split?

DURECT's stock reverse split on Tuesday, December 6th 2022. The 1-10 reverse split was announced on Tuesday, December 6th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, December 6th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of DURECT own?

Based on aggregate information from My MarketBeat watchlists, some companies that other DURECT investors own include Geron (GERN), Catalyst Pharmaceuticals (CPRX), VBI Vaccines (VBIV), MannKind (MNKD), Novavax (NVAX), Cassava Sciences (SAVA), Amarin (AMRN), Matinas BioPharma (MTNB), Inovio Pharmaceuticals (INO) and Verastem (VSTM).

Who are DURECT's major shareholders?

DURECT's stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (3.60%), Vanguard Group Inc. (3.60%), Richmond Brothers Inc. (1.74%), Silverberg Bernstein Capital Management LLC (0.16%), Virtu Financial LLC (0.15%) and Barclays PLC (0.00%). Insiders that own company stock include Gail J Maderis, Gail M Farfel, Judith J Robertson, Judy R Joice, Mohammad Azab and Simon X Benito.
View institutional ownership trends
.

How do I buy shares of DURECT?

Shares of DRRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:DRRX) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners